Prosecution Insights
Last updated: April 19, 2026
Application No. 18/798,973

Curable Polymer Compositions Comprising Heteroatom-Containing Silane Compounds

Non-Final OA §112
Filed
Aug 09, 2024
Examiner
ZIMMER, MARC S
Art Unit
1765
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Henkel AG & Co. KGaA
OA Round
1 (Non-Final)
79%
Grant Probability
Favorable
1-2
OA Rounds
2y 7m
To Grant
95%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allow Rate
1230 granted / 1549 resolved
+14.4% vs TC avg
Strong +16% interview lift
Without
With
+15.6%
Interview Lift
resolved cases with interview
Typical timeline
2y 7m
Avg Prosecution
48 currently pending
Career history
1597
Total Applications
across all art units

Statute-Specific Performance

§101
0.3%
-39.7% vs TC avg
§103
39.2%
-0.8% vs TC avg
§102
27.7%
-12.3% vs TC avg
§112
24.2%
-15.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1549 resolved cases

Office Action

§112
Examiner Zimmer has assumed responsibility for the prosecution of this case from Examiner Empie. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions The restriction requirement has been withdrawn as there was believed to be no burden in search claims 1 to 15, and claim 16, together. Claim Objections Claim 1 and the claims dependent therefrom are objected to because R5 is defined as being encompassing of an oxygen atom but R5 is monovalent and only a single bond is drawn between the variable X and R5 thus leaving one valency of the oxygen atom undefined. It is suggested that Applicant remove mention of “a polydiorganosiloxane” and “a polydimethylsiloxane (PDMS)” insofar as the latter is a species of the former genus and a “polydiorganosiloxane” is, in turn” a species of polyorganosiloxane. The Examiner presumes that the variable “A” in claim 4 does not actually constitute an ester, amine, glycol, etc. but rather a divalent residue/moiety containing one of these groups, as in an ester-containing moiety, an amine-containing moiety, a glycol-containing moiety, etc. Not only would the silicon-A bond be hydrolysable, which is ostensibly undesirable, were A to represent, for instance, an amine but also the actual connectivity of these groups to the silicon group would not be clear and there are maybe even enablement issues present if “A” were to actually denote these groups specifically. How, for instance, would one prepare a compound containing a group Si-A where A was an imide or sulfide group? There should be a space between “R7” and “and” four lines from the bottom in claim 7. Claim 8 is objected to because it curiously recites a Markush group but where three alternatives are mentioned after the conjunction “and”. It is surmised that Applicant may have intended to then indicate that alkoxy groups are a preferred embodiment of R1 and methoxy and ethoxy groups are most preferred but, of course, the disclosure of a broader group followed by a narrow group is grounds for a rejection under 35 U.S.C. 112(b). Accordingly, the Examiner strongly encourages Applicant to simply remove “,alkoxy groups, a methoxy or ethoxy group” from the description of R1. It is further recommended that the first incidence of the word “or” in the description of R4 (line 5) be deleted. In claim 9, it is suggested that the first- and second incidences of the word “or” in the description of R4 (line 2) be deleted. In claim 10, it is recommended that the first incidence of the word “or” in the description of R4 (as in “or an ethyl” in line 2) be deleted. In claim 11, it is suggested that the first incidence of the word “or” in the description of R6, R7, and R8 (as in “or C1 to C20 alkyl in line 2) be deleted. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 4 and 6 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. In claim 4, Applicant employs Markush language to define Ra, Rd, Rf, Rh, and Ri but ends the list of suitable alternatives with “or”, as opposed to “and” casting doubt on the intended scope of these aspects. When Rc is defined, several alternatives are listed NOT as a Markush group but, nevertheless, using “and” to relate the last stated permutation to the others thereby creating questions as to whether or not Rc represents all of the groups from “alkyl” through “heteroalicyclic” simultaneously. Of course, the list is followed by the phrase “or a combination thereof” which connotes the opposite. As for claim 6, it is not evident what would be included within the scope of “a derivative of” the siloxane-alkylene shown. Allowable Subject Matter Claims 1-16 are allowable over the prior art. In general, silane compounds featuring a silicon atom bonded directly to a heterocyclic group are rare. In fact, the Examiner only encountered a couple of examples of a silane compound anticipatory of claimed component (B), and then only in the context of it being a co-monomer in the preparation of a polysiloxane. See Di Giorgio, U.S. Patent # 2,640,818, Frisch et al., U.S. Patent # 2,845,435, Friedrich, AU 2003/231719 at page 14. Most often, heterocyclic groups are bonded to a silicon atom of a silane compound via a linking group and, then, usually via a heteroatom, as opposed to a carbon atom vicinal to a heteroatom. As an aside, the Examiner is cognizant of the fact that formula (I) is encompassing of silanes where the heteroatom X is not part of a heterocyclic ring but a structure search only yielded examples of a structurally compliant compound where the heteroatom was part of a ring and the Examiner could conceive of no other silane compounds containing a silicon atom bonded to an sp2 hybridized carbon and said carbon being, in turn, attached to a heteroatom, nor a synthetic approach by which a non-cyclic congener might be prepared. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARC S ZIMMER whose telephone number is (571)272-1096. The examiner can normally be reached M-F 8:30-5:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Heidi Kelley can be reached at 571-270-1831. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. January 19, 2026 /MARC S ZIMMER/Primary Patent Examiner, Art Unit 1765
Read full office action

Prosecution Timeline

Aug 09, 2024
Application Filed
Jan 19, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600882
SILICONE COMPOSITIONS CONTAINING ACRYLATE CURE ACCELERATOR
2y 5m to grant Granted Apr 14, 2026
Patent 12590186
FLUOROSILICONE POLYMERS, COMPOSITIONS, AND USES THEREOF
2y 5m to grant Granted Mar 31, 2026
Patent 12583209
MULTILAYER BODY COMPOSED OF CURED ORGANOPOLYSILOXANE FILMS, USE OF SAME, AND METHOD FOR PRODUCING SAME
2y 5m to grant Granted Mar 24, 2026
Patent 12584008
POLYOLEFIN COMPOSITION FOR ROOFING APPLICATIONS
2y 5m to grant Granted Mar 24, 2026
Patent 12584053
SILANE FUNCTIONALIZED ROSINS
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
79%
Grant Probability
95%
With Interview (+15.6%)
2y 7m
Median Time to Grant
Low
PTA Risk
Based on 1549 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month